Clinical trial Recruiting at 1 site Observational Ages 18 to 85

Checking for lymph node spread and tumor deposits in the posterior gastric mesentery after distal stomach cancer surgery

Official title: Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery Following D2 Lymphadenectomy Plus Complete Mesogastric Excision in Patients Who Received Distal Gastrectomy: A Prospective Observational Study

Run by First Affiliated Hospital of Zhejiang University · NCT06736847 · Data updated 2026-11-12

This project will check if adults having distal stomach cancer surgery (distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision) have lymph node metastases or tumor deposits in the posterior gastric mesentery.

More Gastric Carcinoma trials

Quick facts

Study typeObservational
Ages18 Years to 85 Years
SexAll
Enrollment200 (estimated)
SponsorFirst Affiliated Hospital of Zhejiang University
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Hangzhou, Zhejiang)
StatusRecruiting
StartedMay 1, 2024
Main results expectedDecember 31, 2027
Study endsDecember 31, 2027
Registry record updatedSeptember 2, 2025
Trial IDNCT06736847 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 to 84 with primary distal gastric adenocarcinoma staged cT2-4N0-3M0 who undergo distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision and meet ASA I–III and other study criteria are ideal candidates.

Probably not a fit

Patients with very advanced or metastatic disease (cT4b/M1), prior neoadjuvant therapy, BMI over 30, prior upper abdominal surgery, total or proximal gastrectomy, or concurrent other malignancies are unlikely to benefit from the protocol findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study of patients who undergo distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision for gastric adenocarcinoma. Surgeons will resect the posterior gastric mesentery during the procedure and pathologists will examine the tissue for metastatic lymph nodes (including No.11p and part of No.11d) and tumor deposits. The number and distribution of positive nodes and any tumor deposits will be recorded and correlated with preoperative staging and clinical features. The study is single-center, conducted at the First Affiliated Hospital, Zhejiang University School of Medicine, and enrolls patients meeting defined inclusion and exclusion criteria.

Why it matters

Potential benefit: If successful, the findings could improve surgical planning and pathological staging by clarifying how often the posterior gastric mesentery harbors metastatic nodes or tumor deposits, potentially reducing recurrence from missed disease.

How similar studies have gone: Previous work, including the DCGC01 findings, suggests D2 plus CME removes more lymph nodes and may improve long-term outcomes, but detailed mapping of metastasis specifically in the posterior gastric mesentery remains relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Aged older than 18 years and younger than 85 years
2. Primary gastric adenocarcinoma confirmed by preoperative pathology result
3. cT2-4N0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 7th Edition
4. Patients who received distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
5. American Society of Anesthesiologists (ASA) class I, II, or III
6. Written informed consent

Exclusion Criteria:

1. Negative preoperative biopsy
2. Too late tumour stage or metastasis (cT4b/M1)
3. BMI\>30 kg/m2
4. Total gastrectomy or proximal gastrectomy
5. previous neoadjuvant chemotherapy or radiotherapy
6. Previous upper abdominal surgery
7. Combined with other malignant diseases
8. Reject operation

Where it's running

  • Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.